Skip to content

Study · Systematic review · n = 2,067 · 2022

3 results

Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.

Shibuki K, Shimada S, Aoyama T

Diabetes & metabolic syndrome28 Mar 2022Cited by 2 (Europe PMC)

PMID35378386 (opens in a new tab)DOI10.1016/j.dsx.2022.102474 (opens in a new tab)PepBankPUB-35378386
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes treated with insulin, pooled trials showed that liraglutide add-on lowered HbA1c, with an adjusted mean change of -1.00%.

    In plain wordsIn adults with type 2 diabetes on insulin, adding liraglutide lowered HbA1c in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseAdjusted mean change in HbA1c (AMΔHbA1c)
    Study

    n = 2,067

    Comparator
    Placebo or insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    AMΔHbA1c
    −1%
    pooled, liraglutide add-on

    Source sentences

    Summary
    AMΔHbA1c was -1.00% (95% confidence interval [CI]: -1.21 to -0.78, I2 = 74.7%).
    2 context sentences
    Summary · context
    We performed a meta-analysis of randomized controlled trials of ≥12 weeks reporting the endpoint of adjusted mean change in hemoglobin A1c levels (AMΔHbA1c) or hypoglycemia incidence.
    Summary · context
    The intervention group received liraglutide co-administered with insulin or a fixed-dose combination.
  2. 02HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes treated with insulin, pooled trials showed no significant change in hypoglycemia incidence with liraglutide add-on (odds ratio 0.97).

    In plain wordsIn adults with type 2 diabetes on insulin, adding liraglutide did not significantly change the chance of low blood sugar in pooled trials.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycemia incidence
    Study

    n = 2,067

    Comparator
    Placebo or insulin
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    0.97
    hypoglycemia incidence

    Source sentences

    Summary
    The odds ratio for hypoglycemia incidence was 0.97 (95% CI: 0.50-1.87, I2 = 81.9%).
    2 context sentences
    Summary · context
    We performed a meta-analysis of randomized controlled trials of ≥12 weeks reporting the endpoint of adjusted mean change in hemoglobin A1c levels (AMΔHbA1c) or hypoglycemia incidence.
    Summary · context
    The intervention group received liraglutide co-administered with insulin or a fixed-dose combination.
  3. 03HumanSystematic reviewOther

    In the pooled liraglutide add-on trials, baseline HbA1c, fasting glucose, BMI, diabetes duration and treatment duration did not account for heterogeneity in HbA1c change or hypoglycemia.

    In plain wordsIn pooled liraglutide add-on trials, the baseline factors checked did not explain the differences between trials.

    Peptide
    Liraglutide
    Outcome
    No significant changeHeterogeneity explained by baseline covariates
    Study

    n = 2,067

    Comparator
    Placebo or insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Covariates did not account for the heterogeneity in AMΔHbA1c or hypoglycemia incidence.
    2 context sentences
    Summary · context
    We performed a meta-analysis of randomized controlled trials of ≥12 weeks reporting the endpoint of adjusted mean change in hemoglobin A1c levels (AMΔHbA1c) or hypoglycemia incidence.
    Summary · context
    The intervention group received liraglutide co-administered with insulin or a fixed-dose combination.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.